{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:45:11Z","timestamp":1777002311264,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.ahj.2008.05.017","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T17:23:39Z","timestamp":1220808219000},"page":"623-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial"],"prefix":"10.1016","volume":"156","author":[{"given":"Robert M.","family":"Califf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitradev","family":"Boolell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Angelyn","family":"Bethel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Duggal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2008.05.017_bib1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.21.4.518","article-title":"Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2008.05.017_bib4","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S0002-8703(99)70037-2","article-title":"Diabetes and ischemic heart disease","volume":"138","author":"McGuire","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.05.017_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib6","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.05.017_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ahj.2008.05.018","article-title":"Determining the most appropriate components for a composite clinical trial outcome","volume":"156","author":"Bethel","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.05.017_bib11","first-page":"S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"22","author":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib12","series-title":"Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus","author":"Alberti","year":"1999"},{"key":"10.1016\/j.ahj.2008.05.017_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2008.05.017_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1210\/edrv-5-3-395","article-title":"Aspects of the pathogenesis of type 2 diabetes","volume":"5","author":"Efendic","year":"1984","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.ahj.2008.05.017_bib15","author":"Novartis Pharmaceutical Corp"},{"key":"10.1016\/j.ahj.2008.05.017_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2337\/diacare.24.7.1221","article-title":"Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)","volume":"24","author":"Gribble","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.05.017_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting\u2013enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib19","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib20","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic","volume":"288","author":"The ALLHAT Investigators","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.05.017_bib21","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.05.017_bib22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-200209000-00035","article-title":"Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study","volume":"20","author":"Lindholm","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2008.05.017_bib23","article-title":"The Study on COgnition and Prognosis in Elderly Hypertensives (SCOPE)","author":"Hansson","year":"2002"},{"key":"10.1016\/j.ahj.2008.05.017_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.05.017_bib25","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib26","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.jhh.1000434","article-title":"Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients","volume":"11","author":"Paolisso","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ahj.2008.05.017_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/147323000203000103","article-title":"The effects of valsartan on insulin sensitivity in patients with primary hypertension","volume":"30","author":"Top","year":"2002","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ahj.2008.05.017_bib29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2008.05.017_bib30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00004872-199609000-00016","article-title":"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril","volume":"14","author":"Holwerda","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2008.05.017_bib32","author":"Novartis Pharmaceutical Corp"},{"key":"10.1016\/j.ahj.2008.05.017_bib33","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc07-1452","volume":"31","author":"Black","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib35","author":"National Heart, Lung, and Blood Institute"},{"key":"10.1016\/j.ahj.2008.05.017_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib37","doi-asserted-by":"crossref","unstructured":"Califf RM, DeMets DL. Lessons learned from recent cardiovascular clinical trials. Parts I and II. Circulation 2002;106:746-51 and 880-6.","DOI":"10.1161\/01.CIR.0000023220.26465.89"},{"key":"10.1016\/j.ahj.2008.05.017_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2337\/diacare.21.3.360","article-title":"High blood glucose concentration is a risk factor for mortality in middle-aged men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study","volume":"21","author":"Balkau","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","article-title":"The relationship between glucose and incident cardiovascular events","volume":"22","author":"Coutinho","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/diacare.2.2.131","article-title":"Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland","volume":"2","author":"Py\u00f6r\u00e4l\u00e4","year":"1979","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2008.05.017_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of WHO criteria and American Diabetic Association diagnostic criteria","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.05.017_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2008.05.017_bib44","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib45","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1001\/jama.289.16.2128","article-title":"Stopping medical research to save money: a broken pact with researchers and patients","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.05.017_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib47","series-title":"The analysis of binary data","author":"Cox","year":"1989"},{"key":"10.1016\/j.ahj.2008.05.017_bib48","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.05.017_bib49","first-page":"1187","article-title":"Disagreements between a central Clinical Events Committee and site investigator assessment of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study","volume":"2","author":"Mahaffey","year":"2001","journal-title":"Curr Contr Trials Cardiovasc Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030800389X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030800389X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:36:17Z","timestamp":1757568977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287030800389X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S000287030800389X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2008.05.017","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2008.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}